Welcome to our dedicated page for Rigel Pharmaceuticals SEC filings (Ticker: RIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rigel Pharmaceuticals' SEC filings document the regulatory record of a Delaware biotechnology company with common stock listed on Nasdaq under RIGL. Its 8-K reports frequently furnish operating results, product revenue trends, collaboration revenue and business updates tied to TAVALISSE, GAVRETO, REZLIDHIA and development programs such as R289.
The filings also cover material agreements, license and collaboration disclosures, capital-structure information for common stock, and governance matters. Proxy materials describe shareholder voting items, board matters, executive compensation and equity awards, while material-event filings record changes affecting agreements, financial reporting and corporate governance.
On 6 Aug 2025, Rigel Pharmaceuticals (RIGL) filed a routine Form S-8 to register 825,000 additional common shares for employee equity compensation: 125,000 shares under the Inducement Plan and 700,000 shares under the 2018 Equity Incentive Plan. The filing incorporates prior S-8s by reference and includes the usual legal opinions, consents and power-of-attorney exhibits; it contains no new earnings, balance-sheet data or corporate actions beyond the share registration. The statement ensures Rigel has sufficient shares available for future option and restricted-stock grants, supporting talent recruitment and retention. While the registration itself does not raise capital, any subsequent issuance of the shares will incrementally dilute existing shareholders.